Insights | Integration🖊️(@con_nectinder) 's Twitter Profile Photo

✅ Drugs & Related News:

Name: Some Insights🗒️

• Semaglutide: sold as a magic drug for weight loss
• Schedule M: Mfg. practices
• Schedule H1: Anti-microbial resistance
• Casgevy & Lyfgenia: 🏳️1st Gene therapy( 🇺🇲 US & UK 🇬🇧)
• Bedaquiline(DR,MDR): Secondary patent

✅ Drugs & Related News: 

 Name: Some Insights🗒️

• Semaglutide: sold as a magic drug for weight loss
• Schedule M: Mfg. practices
• Schedule H1: Anti-microbial resistance 
• Casgevy & Lyfgenia: 🏳️1st Gene therapy( 🇺🇲 US & UK 🇬🇧)
• Bedaquiline(DR,MDR): Secondary patent
account_circle
Dr.Thota Ramarjun⚕💉🇮🇳 O positive 🩸(@ramarjunfollows) 's Twitter Profile Photo

BPaLM regimen
The BPaL regimen (comprised of bedaquiline, pretomanid and linezolid) was first studied,Nix-TB participants with XDR-TB and treatment intolerant or nonresponsive MDR-TB were enrolled for treatment with the BPaL regimen for six months,

account_circle
MSF Science(@MSFsci) 's Twitter Profile Photo

Shorter, less toxic oral regimens to treat multidrug-resistant are available!

Lorenzo Gugilielmetti explains how the new shortened regimen is not only easier for patients but also beneficial for those without access to or

account_circle
Eghar Anugrapaksi(@egharap) 's Twitter Profile Photo

Salah satu uji klinis fenomenal di bidang TB Resisten Obat (TB RO) telah merilis hasil akhirnya.

TB-PRACTECAL menguji apakah kombinasi obat oral Bedaquiline, Pretomanid, dan Linezolid (BPaL), + Moxifloxacin (BPaLM), atau + Clofazimin (BPaLC) yang hanya diminum dalam 6 bulan,

Salah satu uji klinis fenomenal di bidang TB Resisten Obat (TB RO) telah merilis hasil akhirnya. 

TB-PRACTECAL menguji apakah kombinasi obat oral Bedaquiline, Pretomanid, dan Linezolid (BPaL),  + Moxifloxacin (BPaLM), atau + Clofazimin (BPaLC) yang hanya diminum dalam 6 bulan,
account_circle
NIPER Raebareli(@NIPERRaebareli) 's Twitter Profile Photo

Congratulations to Dr. Keerti Jain’s research group for publishing a Research article entitled “Formulation Development, Characterization, and Evaluation of Bedaquiline Fumarate -Soluplus® -Solid Dispersion” in Pharmaceutical Development and Technology (Taylor & Francis)

Congratulations to Dr. Keerti Jain’s research group for publishing a Research article entitled “Formulation Development, Characterization, and Evaluation of Bedaquiline Fumarate -Soluplus® -Solid Dispersion” in Pharmaceutical Development and Technology (Taylor & Francis)
account_circle
The Lancet Infectious Diseases(@TheLancetInfDis) 's Twitter Profile Photo

New research: Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial

thelancet.com/journals/lanin…

account_circle
Luper Bukuku(@luper_bukuku) 's Twitter Profile Photo

'Every person battling MDR-TB deserves access to Bedaquiline – a crucial lifeline in the fight against multidrug-resistant tuberculosis. Let's unite to ensure this life-saving medication reaches those who need it most' Stop TB Partnership

'Every person battling MDR-TB deserves access to Bedaquiline – a crucial lifeline in the fight against multidrug-resistant tuberculosis. Let's unite to ensure this life-saving medication reaches those who need it most' @StopTB
account_circle
Melissa Barber (@mbarber.bsky.social)(@mellabarb) 's Twitter Profile Photo

In response to years of immense public pressure, Johnson & Johnson finally stopped fighting tooth and nail to defend its monopoly on bedaquiline (an MDR-TB drug).

Not even 5 months later they are advertising it before Congress HELP Committee Dems as altruism.

You lost. It's not philanthropy.

account_circle
Antonio Guerrero(@guerreroespejo) 's Twitter Profile Photo

A , pretomanid, moxifloxacin, and pyrazinamide regimen for drug-susceptible and drug-resistant - The Lancet Infectious Diseases
New drug combo shows promise for treating all types of TB, including drug-resistant strains.
👇
thelancet.com/journals/lanin…

account_circle
Roshan(@johnroshanj) 's Twitter Profile Photo

SA CompCom Deputy Commissioner at the CUTS-CIRC conference in Delhi, discussing the power of competition law to increase access. Highlights their probe into JnJ regarding Bedaquiline and praises the public's role in increasing access to the TB drug.

SA CompCom Deputy Commissioner at the CUTS-CIRC conference in Delhi, discussing the power of competition law to increase access. Highlights their probe into JnJ regarding Bedaquiline and praises the public's role in increasing access to the TB drug. #competitionlaw
account_circle
🐢🐢🐢John Green🐢🐢🐢(@johngreen) 's Twitter Profile Photo

!!!!!!!!!!!!! Johnson & Johnson, THANK YOU for choosing . Takes real guts to live up to your credo. Generic bedaquiline WILL BE AVAILABLE in almost every country with a high tuberculosis burden. I am so happy and grateful to the Stop TB Partnership, J&J, and especially

account_circle
Mislav Acman(@misac42) 's Twitter Profile Photo

Our latest paper on drug resistance in tuberculosis (TB) is just published in Genome Medicine – a collective effort lead by the fantastic Lucy van Dorp 🔬👩‍🔬
Full paper here: tinyurl.com/2583zxhj

Our latest paper on drug resistance in tuberculosis (TB) is just published in Genome Medicine – a collective effort lead by the fantastic @LucyvanDorp  🔬👩‍🔬
Full paper here: tinyurl.com/2583zxhj
#TB #DrugResistance #Tuberculosis #Bedaquiline #Genomics #AcademicTwitter
account_circle
Andargachew Kumsa(@akumsa2011) 's Twitter Profile Photo

Made a visit at Bishoftu Hospital DR-TB Referral Care Center, aka Bedaquiline Resort with colleagues Malawi, Kenya, Tanzania, Uganda, South Africa. Witnessed that the first patient enrolled on BPaLM Regimen in the hospital is cured!Very exciting news! Lucica Ditiu Tereza Kasaeva

Made a visit at Bishoftu Hospital DR-TB Referral Care Center, aka Bedaquiline Resort with colleagues Malawi, Kenya, Tanzania, Uganda,  South Africa. Witnessed that the first patient enrolled on BPaLM Regimen in the hospital is cured!Very exciting news! @LucicaDitiu @TerezaKasaeva
account_circle
🐢🐢🐢John Green🐢🐢🐢(@johngreen) 's Twitter Profile Photo

BIG NEWS: Johnson & Johnson just publicly confirmed it will not enforce its secondary bedaquiline patents in ANY of 134 low- and middle-income countries. That's HUGE. Full credit to Johnson & Johnson for this commitment. This is what we've been waiting for. jnj.com/johnson-johnso…

account_circle
Lancelot Pinto(@lancelot_pinto) 's Twitter Profile Photo

Just received this message. Is Bedaquiline being sold at pharmacies?Given the track-record of antibiotic abuse and irrational prescriptions for TB,this has the potential for making us lose a precious drug for MDR TB. Chapal Mehra Malathy Iyer Nandita V Soumya Swaminathan

Just received this message. Is Bedaquiline being sold at pharmacies?Given the track-record of antibiotic abuse and irrational prescriptions for TB,this has the potential for making us lose a precious drug for MDR TB. @ChapalMehra @MalathyIyerTOI @nandita_venky @doctorsoumya
account_circle
Timothy Li(@drtimothyli) 's Twitter Profile Photo

One interesting fact I learned today about this weird antibiotic:

Cross-resistance of clofazimine and bedaquiline can occur due to mutations in Rv0678
Therefore previous exposure to clofazimine might lead to bedaquiline resistance without previous bedaquiline exposure

account_circle
Clockwork(@this_clockwork) 's Twitter Profile Photo

Bedaquiline (orange) inhibiting Tuberculosis ATP production by binding to the F0 ring of a mycobacterial ATP Synthase complex (green). Bedaquiline is a critical weapon in the fight against drug-resistant TB that attacks the bacterium's biochemical foundations.

Bedaquiline (orange)  inhibiting Tuberculosis ATP production by binding to the F0 ring of a mycobacterial ATP Synthase complex (green). Bedaquiline is a critical weapon in the fight against drug-resistant TB that attacks the bacterium's biochemical foundations. #sciart
account_circle
UNITE4TB(@UNITE4TB) 's Twitter Profile Photo

The final session of our 2024 Annual Meeting is a panel discussion about responding to the emerging threat of bedaquiline resistance. Innovative Health Initiative IMI AMR ACCELERATOR

The final session of our 2024 Annual Meeting is a panel discussion about responding to the emerging threat of bedaquiline resistance. @IHIEurope @AMRAccelerator
account_circle